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Introduction {#clc22504-sec-0006}
============

Symptomatic sinoatrial node disease represents a constellation of signs and symptoms that signify the heart\'s inability to perform its pacemaker function. Manifestations of disease include sinus bradycardia, sinus pauses or arrest, chronotropic incompetence, and alternating atrial bradyarrhythmias and tachyarrhythmias, referred to as the bradycardia‐tachycardia syndrome.[1](#clc22504-bib-0001){ref-type="ref"} Sinus node dysfunction (SND) may become manifest due to age, genetics, disease, and/or medications.

In the elderly and in patients with many types of comorbidities, most often degenerative change and/or fibrosis of the atrial myocardium and conduction system are responsible for the clinical manifestations of both atrial fibrillation (AF) and SND. In addition, AF itself can cause detrimental remodeling throughout the right atrium, including the sinus node and its vascular supply,[2](#clc22504-bib-0002){ref-type="ref"}, [3](#clc22504-bib-0003){ref-type="ref"}, [4](#clc22504-bib-0004){ref-type="ref"} leading to slowed conduction, sinoatrial exit block, low‐voltage amplitude signals, and myocardial scarring.[5](#clc22504-bib-0005){ref-type="ref"}, [6](#clc22504-bib-0006){ref-type="ref"} Treatment of SND in patients with AF can include permanent pacing to prevent the consequences of postconversion pauses after AF, treatment of chronotropic incompetence, prevention of the clinical sequelae of antiarrhythmic drug--induced aggravation of conduction system disease, and additional rate control in those patients with episodes of AF with rapid ventricular response.

To date, the treatment patterns and outcomes from a contemporary group of patients with AF and SND have not been well characterized. Accordingly, we used the Outcomes Registry for Better Informed Treatment--Atrial Fibrillation (ORBIT‐AF) to describe the prevalence, clinical characteristics, treatment, and outcomes associated with SND. We hypothesized that patients with SND and AF would have more symptomatic AF, with higher risk of adverse cardiovascular outcomes.

Methods {#clc22504-sec-0007}
=======

Study Population {#clc22504-sec-0008}
----------------

The ORBIT‐AF registry is a prospective, multicenter registry of patients with AF from across the United States managed by a variety of providers including internists, general cardiologists, and electrophysiologists. The rationale and design of the ORBIT‐AF registry have been previously described.[7](#clc22504-bib-0007){ref-type="ref"} Briefly, eligible patients included those age ≥18 years with electrocardiographically documented AF who were able to provide written informed consent and to comply with regularly scheduled follow‐up visits. As ORBIT‐AF was an observational registry, all treatment decisions were left to the discretion of the individual treating physicians in accordance with practice guidelines, recommendations, and local standards of care, as was the determination as to whether SND was present.

Data Collection and Study Endpoints {#clc22504-sec-0009}
-----------------------------------

The ORBIT‐AF case‐report form queried each treating physician to indicate whether patients carried a clinical diagnosis of SND as determined by the treating physician. For the purpose of this analysis, patients were stratified by the presence or absence of SND and the presence or absence of a permanent pacing device, including only pacemakers and not cardiac resynchronization therapy. The purpose of stratifying patients based on the presence or absence of a permanent pacing device was to evaluate the effects of pacing on AF progression. The primary outcomes included first progression of AF, defined as having paroxysmal AF at baseline visit to persistent or permanent AF at any follow‐up, or persistent AF at baseline visit to permanent AF at any follow‐up; all‐cause death; cardiovascular death; first rehospitalization (all cause); first major bleeding; first stroke/transient ischemic attack; first new‐onset heart failure (HF); European Heart Rhythm Association (EHRA) score; and Atrial Fibrillation Effect on Quality of Life (AFEQT) score.[8](#clc22504-bib-0008){ref-type="ref"} Primary outcomes were not adjudicated by a clinical events committee but reported by site investigators. All outcomes, except EHRA score, were defined from the baseline visit to the last follow‐up (median, 24 months; 25th and 75th percentiles, 18 and 24 months). The EHRA score was defined at 1‐year follow‐up.

Statistical Analysis {#clc22504-sec-0010}
--------------------

Baseline characteristics were compared between the 2 groups, including demographics, medical history, CHA~2~DS~2~‐VASc risk scores, echocardiographic assessment, procedures, and medical therapies. The data are presented as medians (interquartile range) for continuous variables and as proportions for categorical variables. For univariate analysis, the differences across 2 groups were assessed using the Wilcoxon rank‐sum test for continuous variables and the χ^2^ test for categorical variables. Treatment patterns at baseline for patients with and without SND are presented as proportions. Outcomes assessments by 2 groups (SND vs no SND) are presented as unadjusted and adjusted risk estimates (hazard ratio) of SND vs no SND and corresponding 95% confidence interval (CI) from a Cox frailty model. This approach allows for the inclusion of a random effect for site within a proportional hazards model, accounting for potential heterogeneities between sites. For AF progression, which was captured only at visit intervals, unadjusted and adjusted odds ratios (OR) of SND vs no SND were calculated using regression discrete time, proportional odds model. Each outcome model is adjusted for a previously identified set of significant covariates, identified from a large candidate list by backward selection, with an α for exclusion of 0.05. To assess the possibility of confounding by pacemaker status, 1 additional covariate (pacemaker) was included in each model. Missing covariate data in the regression analysis (\<14%) were handled by multiple imputation using Markov chain Monte Carlo and regression methods. Final estimates and associated SEs reflect the combined analysis over 5 imputed data sets.

The ORBIT‐AF study was approved by the Duke Institutional Review Board, and all participating sites obtained institutional review board approval pursuant to local requirements. All subjects provided written informed consent. All statistical analyses were performed at the Duke Clinical Research Institute using SAS software version 9.3 (SAS Institute, Inc., Cary, NC).

Results {#clc22504-sec-0011}
=======

Baseline Characteristics {#clc22504-sec-0012}
------------------------

Between June 29, 2010, and August 09, 2011, 10 132 AF patients were enrolled in the ORBIT‐AF registry. The current analysis excluded 501 patients due to incomplete follow‐up. This yielded a final study population of 9631 patients with ≥1 follow‐up from 174 sites. Baseline characteristics of the study cohort are shown in tables [1](#clc22504-tbl-0001){ref-type="table"} and [2](#clc22504-tbl-0002){ref-type="table"} according to the presence or absence of SND. Among 9631 AF patients, 1710 (17.7%) had the impression of SND as documented by the treating physician, whereas 7921 (82.2%) had no impression of SND. Patients with SND were more likely to have hypertension, coronary artery disease, valvular heart disease, heart failure (HF) thyroid disease, prior cerebrovascular events, prior interventional therapy for AF, and lower left ventricular ejection fraction. They also had higher CHA~2~DS~2~‐VASc risk scores and higher use of oral anticoagulants (OAC), but lower AFEQT scores at 12 months. Patients without SND were less likely to have implanted devices, were of younger age, and more likely to have sinus rhythm on most recent 12‐lead ECG.

###### 

Baseline Characteristics by the Presence or Absence of SND

                                                                   Overall, N = 9631   Without SND, n = 7921   With SND, n = 1710  P Value
  --------------------------------------------------------------- ------------------- ----------------------- -------------------- ----------
  Age, y                                                              75 (67--82)           74 (66--81)           79 (72--84)      \<0.0001
  Male sex                                                                57                    58                     56          0.15
  Race                                                                                                                             \<0.0001
  White                                                                   89                    89                     93          
  African American                                                        4.9                   5.2                   3.5          
  Hispanic                                                                4.1                   4.5                   2.2          
  Asian                                                                   0.6                   0.7                   0.4          
  Other                                                                   0.3                   0.3                   0.2          
  Medical history                                                                                                                  
  HTN                                                                     83                    83                     86          0.0002
  Hyperlipidemia                                                          72                    71                     77          \<0.0001
  Smoking                                                                 49                    48                     50          0.1
  Thyroid disease                                                         23                    22                     26          \<0.0001
  OSA                                                                     18                    18                     19          0.7
  DM                                                                      29                    29                     30          0.4
  CAD                                                                     36                    34                     45          \<0.0001
  HF                                                                      33                    31                     42          \<0.0001
  Implanted device                                                        28                    16                     83          \<0.0001
  Pacemaker                                                               19                    7.6                    70          \<0.0001
  Significant valvular disease                                            26                    24                     33          \<0.0001
  Prior cerebrovascular events                                            16                    15                     20          \<0.0001
  Stroke (all cause)                                                      8.9                   8.3                    11          0.0001
  Nonhemorrhagic                                                          8.0                   7.5                    10          0.0003
  Hemorrhagic                                                             0.8                   0.7                   1.0          0.2
  TIA                                                                     8.2                   7.7                    11          \<0.0001
  Cognitive impairment/dementia                                           3.0                   2.8                   4.0          0.01
  Frailty                                                                 5.9                   5.4                   8.6          \<0.0001
  GI bleeding                                                             9.2                   8.9                    11          0.03
  BMI, kg/m^2^                                                        29 (25--34)           29 (26--34)           28 (25--33)      \<0.0001
  HR, bpm                                                             70 (63--80)           70 (62--80)           70 (64--78)      0.3
  SBP, mm Hg                                                        126 (116--138)        126 (116--138)         126 (116--136)    0.7
  DBP, mm Hg                                                          72 (66--80)           72 (66--80)           70 (64--80)      \<0.0001
  CrCl[a](#clc22504-note-0008){ref-type="fn"}, mL/min/1.73 m^2^       69 (50--96)           72 (51--99)           60 (44--81)      \<0.0001
  LA diameter, cm                                                    4.4 (3.9--5)          4.4 (3.9--5)            4.4 (4--5)      0.9
  LVEF, %                                                             55 (50--61)           57 (50--62)           55 (48--60)      \<0.0001

Abbreviations: BMI, body mass index; CAD, coronary artery disease; CrCl, creatinine clearance; DBP, diastolic blood pressure; DM, diabetes mellitus; GI, gastrointestinal; HF, heart failure; HR, heart rate; HTN, hypertension; IQR, interquartile range; LA, left atrium; LVEF, left ventricular ejection fraction; OSA, obstructive sleep apnea; SBP, systolic blood pressure; SND, sinus node dysfunction; TIA, transient ischemic attack.

Values are presented as % or median (IQR).

Calculated by Cockcroft‐Gault formula.

###### 

AF History by Presence or Absence of SND

                                                       Overall, N = 9631   Without SND, n = 7921   With SND, n = 1710   P Value
  --------------------------------------------------- ------------------- ----------------------- -------------------- ----------
  AF type                                                                                                               \<0.0001
  First detected/new onset                                    4.5                   5.2                   1.1          
  Paroxysmal                                                  51                    50                     56          
  Persistent                                                  17                    17                     14          
  Permanent                                                   28                    28                     29          
  Duration of AF diagnosis, mo                            48 (18--94)           44 (16--91)           60 (30--109)      \<0.0001
  Sinus rhythm on most recent ECG                             34                    36                     25           \<0.0001
  EHRA symptom level                                                                                                   
  No symptoms                                                 38                    39                     36            0.0007
  Mild                                                        45                    45                     45          
  Severe                                                      15                    14                     17          
  Disabling                                                   1.8                   1.8                   1.5          
  CHADS~2~ risk groups                                                                                                  \<0.001
  0                                                           6.3                   7.1                   2.6          
  1                                                           22                    23                     15          
  ≥2                                                          72                    70                     82          
  CHA~2~DS~2~‐VASc score                                   4 (3--5)              4 (3--5)               5 (3--6)        \<0.0001
  ATRIA score \>4                                            17.3                  16.2                   22.2          \<0.0001
  Current warfarin use                                        72                    71                     76           \<0.0001
  Dabigatran[a](#clc22504-note-0011){ref-type="fn"}           4.9                   5.2                   3.4            0.002
  ASA                                                         44                    44                     45             0.8
  Current AAD                                                 29                    29                     29             0.6
  Prior treatment with AAD                                    54                    56                     47           \<0.0001
  Prior cardioversions                                        30                    31                     29             0.1
  Current AF management strategy                                                                                          0.1
  Rate control                                                68                    68                     70          
  Rhythm control                                              32                    32                     30          
  AF symptoms                                                                                                          
  Syncope/fainting                                            4.4                   4.1                   6.1            0.0003
  Lightheadedness/dizziness                                   20                    20                     23            0.0007
  Prior interventional therapy for AF                         11                    10                     16           \<0.0001
  Catheter ablation of AF                                     5.6                   5.5                   6.0             0.5
  Atrial flutter ablation                                     2.7                   2.4                   3.8            0.001
  AV node/His bundle ablation                                 2.3                   1.7                   4.6           \<0.0001
  Surgical/maze/hybrid maze procedure                         2.0                   1.8                   2.9            0.003
  AFEQT score at 12 mo                                    84 (70--94)           85 (72--94)           80 (67--93)        0.0008

Abbreviations: AAD, antiarrhythmic drug; AF, atrial fibrillation; AFEQT, Atrial Fibrillation Effect on Quality of Life; ASA, aspirin; ATRIA, Anticoagulation and Risk Factors in Atrial Fibrillation; AV, AV node; CHADS~2~, congestive heart failure, HTN, age ≥75 y, DM, prior stroke/TIA/TE; CHA~2~DS~2~‐VASc, congestive heart failure, HTN, age ≥75 y, DM, stroke/TIA, vascular disease, age 65--74 y, sex category (women); DM, diabetes mellitus; ECG, electrocardiogram; EHRA, European Heart Rhythm Association; HTN, hypertension; IQR, interquartile range; OAC, oral anticoagulant; ORBIT‐AF, Outcomes Registry for Better Informed Treatment--Atrial Fibrillation; SND, sinus node dysfunction; TE, thromboembolism; TIA, transient ischemic attack.

Values are presented as % or median (IQR).

ORBIT‐AF registry participation began prior to dabigatran approval, which reflects the small number of patients treated with dabigatran and no patients treated with other non--vitamin K antagonist oral antagonist such as rivaroxaban or apixaban.

Pharmacotherapy {#clc22504-sec-0013}
---------------

Unadjusted rates for both OAC and pharmacologic therapy for AF differed between groups. Current warfarin use was higher in those patients with SND and a CHA~2~DS~2~‐VASc risk scores ≥2 compared with patients without SND and comparable CHA~2~DS~2~‐VASc risk scores (76.2% vs 73.0%; P = 0.0079). In addition, OAC use (warfarin or dabigatran) was higher in patients with SND (79.2% vs 75.9%; P = 0.0035). Between 6% and 10% of patients with SND and AF were not treated with OACs in the absence of a perceived contraindication. Rate control therapy with β‐blockers was similar for those patients with SND vs those without (64.4% vs 64.4%; P = 0.92), whereas calcium channel blocker use was higher in patients without SND (31.0% vs 27.3%; P = 0.0025). Current membrane‐active antiarrhythmic drug use at baseline was not significantly different in those patients with SND vs those without SND (29.3% vs 28.7%; P = 0.62), whereas previous use of antiarrhythmic drugs was higher in patients with SND (55.7% vs 47.5%; P \< 0.0001). In addition, current membrane‐active antiarrhythmic drug use at baseline was not significantly different in those patients with SND without a pacemaker vs patients with SND and pacemaker (29.1% vs 29.4%; P = 0.89). There were no differences in the current AF management strategy between patients with SND vs those without (rate control, 69.7% vs 67.7%; rhythm control, 30.0% vs 32.0%; P = 0.11).

Major Risk‐Adjusted Outcomes {#clc22504-sec-0014}
----------------------------

Unadjusted rates for outcomes are shown in (Figure [1](#clc22504-fig-0001){ref-type="fig"}). Patients with SND had higher rates of AF progression (19.0% vs 15.6%, P = 0.0012; unadjusted OR: 1.18, 95% CI: 1.04‐1.35) and all‐cause mortality (6.7% vs 5.1%, P = 0.0011; unadjusted OR: 1.28, 95% CI: 1.08‐1.51) than did patients without SND. For all other outcomes, except for first stroke, patients with SND had higher risk of each event than those without SND before adjustment (Figure [1](#clc22504-fig-0001){ref-type="fig"}). After adjustment for differences in baseline variables, SND was associated with a higher risk of AF progression (adjusted OR: 1.23, 95% CI: 1.01‐1.49), but there was no association between SND and any of the other outcomes assessed (Figure [2](#clc22504-fig-0002){ref-type="fig"}) (See supporting information, Table 1, in the online version of this article).

![Unadjusted outcomes for patients with SND vs no SND. Abbreviations: AF, atrial fibrillation; HF, heart failure; SND, sinus node dysfunction.](CLC-39-119-g001){#clc22504-fig-0001}

![Adjusted outcomes for patients with SND vs no SND. Abbreviations: AF, atrial fibrillation; CI, confidence interval; HF, heart failure; HR, hazard ratio; SND, sinus node dysfunction.](CLC-39-119-g002){#clc22504-fig-0002}

To assess for the possibility of confounding, 1 additional covariate (pacemaker) was added in each final model. After adjustment, we found that the association between SND and AF progression was no longer significant after adjusting for pacemaker implantation (adjusted OR: 1.11, 95% CI: 0.86‐1.43; Table [3](#clc22504-tbl-0003){ref-type="table"}). In addition, after adjusting for pacemaker implantation, there was no statistically significant difference between patients with SND and those without SND for all other outcomes.

###### 

HR of SND (vs no SND) and Pacemaker (vs no Pacemaker) and 95% CI by Adjusting for Pacemaker Status in Final Adjusted Models

  Outcome                                                              Adjusted OR (95% CI)[a](#clc22504-note-0013){ref-type="fn"}   P Value
  ------------------------------------------------------- ----------- ------------------------------------------------------------- ---------
  AF progression[b](#clc22504-note-0014){ref-type="fn"}   SND                               1.11 (0.86‐1.43)                         0.4250
                                                          Pacemaker                         1.19 (0.97‐1.45)                         0.0916
  AF progression[c](#clc22504-note-0015){ref-type="fn"}   SND                               1.08 (0.87‐1.33)                         0.4934
                                                          Pacemaker                         1.08 (0.90‐1.29)                         0.3944

Abbreviations: AF, atrial fibrillation; CI, confidence interval; ECG, electrocardiogram; HR, hazard ratio; OR, odds ratio; SND, sinus node dysfunction.

For AF progression, we presented OR and corresponding robust 95% CI.

Final risk factors including ECG‐AF (atrial flutter/atrial fibrillation) were adjusted for.

Final risk factors excluding ECG‐AF were adjusted for.

In comparing outcomes of patients with SND between 2 treatment groups (pacemaker vs no pacemaker), both unadjusted and adjusted rates of each outcome failed to show a statistically significant difference (Figure [3](#clc22504-fig-0003){ref-type="fig"}).

![Unadjusted outcomes for patients with SND (pacemaker vs no pacemaker). Abbreviations: SND, sinus node dysfunction.](CLC-39-119-g003){#clc22504-fig-0003}

Discussion {#clc22504-sec-0015}
==========

This study examined the differences in patient characteristics, treatment patterns, and outcomes among a large sample of patients with clinically determined SND. Our analysis yielded several important findings: (1) SND is common among patients with AF; (2) SND is accompanied by increased comorbid illnesses, including risk factors for AF progression such as hypertension, coronary artery disease, HF, valvular heart disease, and older age; (3) SND is associated with higher symptom burden; (4) AF progression is associated with SND; and (5) SND is not associated with worse CV outcomes.

The ORBIT‐AF registry represents the largest contemporary registry of patients with SND. The findings that patients with SND have higher rates of comorbid medical illness as well as more symptoms related to AF suggest that this population is older, with higher comorbidities (tables [1](#clc22504-tbl-0001){ref-type="table"} and [2](#clc22504-tbl-0002){ref-type="table"}). We also observed an increase in mortality of 28% for patients with SND and AF (vs no SND; hazard ratio: 1.28, 95% CI: 1.08‐1.51, *P* = 0.0011). Although these data are unadjusted for confounding and demonstrate no difference after adjustment, it suggests that this subgroup constitutes a population, as expected, that is less healthy, with an increased number of comorbid illnesses and increased risk of mortality.

The classification of patients with AF into SND and non‐SND groups is important because of the limitations on the type of medical therapies that can be used in patients with SND without a pacemaker and the likelihood of future pacemaker requirements. Management of symptoms with pharmacologic therapy for patients with AF and SND did not differ from that of patients with AF alone (Table [2](#clc22504-tbl-0002){ref-type="table"}). These results are unexpected, as we hypothesized a higher use of antiarrhythmic drug (AAD) therapy for rhythm control in those patients with pacemakers implanted for SND. These results are concerning, because the current AF guidelines consider pharmacological therapy in patients with AF and advanced sinus‐node disease a class III recommendation, unless a functioning cardiac pacemaker has been implanted.[9](#clc22504-bib-0009){ref-type="ref"} We present a total cohort of 1710 patients in the ORBIT‐AF registry with SND, of which 519 (30%) were not treated with a pacing system (Table [1](#clc22504-tbl-0001){ref-type="table"}). The fact that approximately 30% of patients with SND, not treated with a pacing system, were treated with AAD, highlights several points: (1) there is a continuum of severity and symptom presentation for patients with SND; (2) improved implementation of evidence‐based guidelines is needed for those patients with severe symptoms attributable to SND, treated with pharmacological drug therapy without a pacemaker, a class III indication; and (3) the definition of SND in the ORBIT‐AF registry may be overly inclusive, selecting for patients with objective signs of SND but with minimal to no symptoms of disease.

Prior to multivariable adjustment, SND was associated with AF progression (Figure [1](#clc22504-fig-0001){ref-type="fig"}). After adjustment for the presence of a pacemaker, the association between patients with SND and AF progression was no longer significant (Table [3](#clc22504-tbl-0003){ref-type="table"}). There are several possibilities from these findings: (1) patients with SND may experience progression of AF due to increased comorbid medical illnesses; and (2) the addition of a pacemaker helped define a population of patients with SND and severe disease who would be expected to have increased risk factors for AF, including degenerative disease and fibrosis of the atrial myocardium, and subsequently, adjusting for the presence of a pacemaker negated its overall impact. Our results regarding the effect on pacing on SND, and in particular on AF progression, should be interpreted cautiously. Physiologic DDD pacing, in conjunction with treatment with atrioventricular nodal blocking agents and membrane‐active AAD, may have prevented AF progression. Conversely, VVI pacing, which can lead to the progression to more persistent forms of AF and increase the risk of HF,[10](#clc22504-bib-0010){ref-type="ref"}, [11](#clc22504-bib-0011){ref-type="ref"} may have provoked AF progression; and hence, after adjustment for pacemaker, the detrimental effects of SND on AF progression were negated. The findings of no difference in the rate of AF progression between patients with SND and a pacemaker vs patients with SND without a pacing system (Figure [3](#clc22504-fig-0003){ref-type="fig"}), in conjunction with no difference in the use of membrane‐active AAD between the 2 groups, suggest that the electrical and mechanical alterations caused by pacing may not be the primary determinant in AF progression. Undoubtedly, AF progression in patients with SND is a complex process that is multifactorial in its etiology, stemming from the interplay between drug therapy, pacing, and comorbid medical illness.

Study Limitations {#clc22504-sec-0016}
-----------------

Several limitations need to be acknowledged in the interpretation of these data. The data presented are derived from a voluntary, observational cohort, and thus are susceptible to residual unmeasured confounding that may impact the validity of our results. Reporting and sampling bias may have affected the designation of SND. The lack of a definition that encompassed the nuances of severity or types of SND may have led to an overinclusive selection of patients with few symptoms related to SND, as evidenced by the high percentage of patients with SND (17%) in this registry. We were unable to conclude whether a specific type of rate‐ or rhythm‐control agent affected AF progression. Adjusting for pacemaker in a multivariate fashion may have attenuated the results with respect to the findings that there was no evidence of an association between SND and AF progression. In addition, AF progression could not be assessed based on different manifestations of SND. The inability to characterize the mode of pacing limits the ability to interpret whether pacing mode affects AF progression.

Conclusion {#clc22504-sec-0017}
==========

In the ORBIT‐AF registry, patients with SND were common and more likely to have increased medical comorbidities and higher symptom burden. Our study did not find any difference in major risk‐adjusted outcomes between patients with SND and AF compared with patients with AF alone.

Supporting information
======================

###### 

Supplemental Table 1. Unadjusted and adjusted outcomes of patients with and without SND

###### 

Click here for additional data file.
